CD274 and cancer: Over the recent years, immune checkpoint inhibitors (ICIs), such as programmed death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, have been studied in different types of cancers, including urothelial cancer, showing robust antitumor activity and a tolerable safety profile14,15.